Advertisement

Protection from clinical peripheral sensory neuropathy in Alström Syndrome in contrast to early onset type2 diabetes

  1. Richard B. Paisey, MD (richard.paisey{at}nhs.net)1,
  2. Rosamund M. Paisey, RGN1,
  3. Mary P. Thomson, PhD1,
  4. Lynne Bower, BSc1,
  5. Pietro Maffei, MD3,
  6. Julian P H Shield, MD2,
  7. Sue Barnett, PhD2 and
  8. Jan D. Marshall, BA4
  1. 1Torbay Hospital, Torquay, UK
  2. 2Bristol Royal Hospital for Children, Bristol, UK
  3. 3Department of Medical and Surgical Science, University School of Medicine, Padua, Italy
  4. 4The Jackson Laboratory, Bar Harbor, ME, USA

    Abstract

    Objective: Alström syndrome, with type 2 diabetes, and blindness could confer a high risk of foot ulceration. Clinical testing for neuropathy in Alström syndrome and matched young onset type 2 diabetic subjects was therefore undertaken.

    Research design and methods: Fifty eight subjects with Alström syndrome, aged 8-43 years (18 insulin resistant, non-diabetic and 40 diabetic) and thirty young onset diabetic subjects aged 13-35 years were studied. Neuropathy symptom questionnaires were administered. Graded monofilament and 128MHz tuning fork vibration perception were assessed in both feet.

    Results: Neuropathic symptoms, loss of monofilament and/or vibration perception were reported by 12 of the 30 young type 2 diabetic subjects (six had neuropathic ulceration) but none of the subjects with Alström syndrome.

    Conclusions: The striking preservation of protective foot sensation in Alström syndrome may provide a clue to the causes of differential susceptibility to neuropathy in the wider diabetic population.

    Footnotes

      • Received August 29, 2008.
      • Accepted December 4, 2008.
    Advertisement